Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Melanoma”

168 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 168 results

Early research (Phase 1)Ended earlyNCT00492440
What this trial is testing

Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer

Who this might be right for
Kidney CancerMelanoma (Skin)
Cytheris SA 9
Testing effectiveness (Phase 2)Study completedNCT04526899
What this trial is testing

Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

Who this might be right for
Melanoma Stage IIIMelanoma Stage IVUnresectable Melanoma
BioNTech SE 184
Testing effectiveness (Phase 2)Ended earlyNCT05551117
What this trial is testing

Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Who this might be right for
Castration-Resistant Prostatic CancerAndrogen-Independent Prostatic CancerAndrogen-Insensitive Prostatic Cancer+14 more
MacroGenics 192
Early research (Phase 1)Ended earlyNCT07121829
What this trial is testing

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorPilocytic Astrocytoma+7 more
Day One Biopharmaceuticals, Inc. 44
Testing effectiveness (Phase 2)Study completedNCT04493203
What this trial is testing

Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

Who this might be right for
Advanced MelanomaUnresectable Melanoma
Yana Najjar 31
Early research (Phase 1)Study completedNCT00019019
What this trial is testing

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerKidney Cancer+6 more
National Institutes of Health Clinical Center (CC) 70
Testing effectiveness (Phase 2)Ended earlyNCT00729807
What this trial is testing

0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma

Who this might be right for
Melanoma (Skin)
University of Maryland, Baltimore 6
Early research (Phase 1)Study completedNCT00004065
What this trial is testing

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Who this might be right for
Bladder CancerBreast CancerColorectal Cancer+9 more
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Looking for participantsNCT06910657
What this trial is testing

IDOV-Immune for Advanced Solid Tumors

Who this might be right for
Colorectal CancerPancreatic CancerMelanoma+13 more
ViroMissile, Inc. 78
Early research (Phase 1)Ended earlyNCT00629187
What this trial is testing

Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

Who this might be right for
Central Nervous System NeoplasmsNeoplasm Metastasis
Tufts Medical Center 2
Early research (Phase 1)Study completedNCT01425008
What this trial is testing

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Who this might be right for
MelanomaMetastatic MelanomaSolid Tumor+1 more
Millennium Pharmaceuticals, Inc. 149
Testing effectiveness (Phase 2)Looking for participantsNCT06594991
What this trial is testing

Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Who this might be right for
Advanced Melanoma
Memorial Sloan Kettering Cancer Center 88
Early research (Phase 1)Study completedNCT01625351
What this trial is testing

CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Who this might be right for
Ewing SarcomaGastrointestinal TumorGerm Cell Tumor+10 more
St. Jude Children's Research Hospital 23
Not applicableEnded earlyNCT00965861
What this trial is testing

SCRI Tissue Testing Registry

Who this might be right for
MelanomaMyelodysplastic SyndromeMultiple Myeloma+1 more
SCRI Development Innovations, LLC 20
Testing effectiveness (Phase 2)Looking for participantsNCT03686124
What this trial is testing

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Who this might be right for
Refractory CancerRecurrent CancerSolid Tumor, Adult+1 more
Immatics US, Inc. 375
Testing effectiveness (Phase 2)Study completedNCT00019383
What this trial is testing

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Who this might be right for
Melanoma (Skin)
National Cancer Institute (NCI)
Early research (Phase 1)Ended earlyNCT02313012
What this trial is testing

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Who this might be right for
Neoplasm Metastasis
Celgene 19
Not applicableWithdrawnNCT00378781
What this trial is testing

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Who this might be right for
Cancer
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT01017185
What this trial is testing

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Who this might be right for
Refractory Head and Neck CancerSquamous Cell Carcinoma, SkinCarcinoma of the Breast+1 more
Takara Bio Inc. 28
Testing effectiveness (Phase 2)Looking for participantsNCT06229340
What this trial is testing

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Who this might be right for
RAS MutationRas (Kras or Nras) Gene MutationColorectal Cancer Recurrent+4 more
N.N. Petrov National Medical Research Center of Oncology 20
Load More Results